Switch theme
Sign up to access all valuation multiples
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
2008
86
LTM Revenue $7.1M
LTM EBITDA -$32.6M
$54.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
InspireMD has a last 12-month revenue (LTM) of $7.1M and a last 12-month EBITDA of -$32.6M.
In the most recent fiscal year, InspireMD achieved revenue of $7.0M and an EBITDA of -$33.2M.
InspireMD expects next 12-month revenue of XXX and NTM EBITDA of XXX
See InspireMD valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $7.1M | XXX | $7.0M | XXX | XXX | XXX |
| Gross Profit | $1.7M | XXX | $1.5M | XXX | XXX | XXX |
| Gross Margin | 24% | XXX | 21% | XXX | XXX | XXX |
| EBITDA | -$32.6M | XXX | -$33.2M | XXX | XXX | XXX |
| EBITDA Margin | -460% | XXX | -474% | XXX | XXX | XXX |
| EBIT | -$42.3M | XXX | -$33.5M | XXX | XXX | XXX |
| EBIT Margin | -596% | XXX | -478% | XXX | XXX | XXX |
| Net Profit | -$41.1M | XXX | -$32.0M | XXX | XXX | XXX |
| Net Margin | -579% | XXX | -457% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, InspireMD's stock price is $3.
InspireMD has current market cap of $77.8M, and EV of $54.0M.
See InspireMD trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $54.0M | $77.8M | XXX | XXX | XXX | XXX | $-0.87 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, InspireMD has market cap of $77.8M and EV of $54.0M.
InspireMD's trades at 7.7x EV/Revenue multiple, and -1.6x EV/EBITDA.
Equity research analysts estimate InspireMD's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
InspireMD has a P/E ratio of -1.9x.
See valuation multiples for InspireMD and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $77.8M | XXX | $77.8M | XXX | XXX | XXX |
| EV (current) | $54.0M | XXX | $54.0M | XXX | XXX | XXX |
| EV/Revenue | 7.6x | XXX | 7.7x | XXX | XXX | XXX |
| EV/EBITDA | -1.7x | XXX | -1.6x | XXX | XXX | XXX |
| EV/EBIT | -1.3x | XXX | -1.6x | XXX | XXX | XXX |
| EV/Gross Profit | 31.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.9x | XXX | -2.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialInspireMD's last 12 month revenue growth is 49%
InspireMD's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.4M for the same period.
InspireMD's rule of 40 is -288% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
InspireMD's rule of X is -337% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for InspireMD and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 49% | XXX | 48% | XXX | XXX | XXX |
| EBITDA Margin | -460% | XXX | -474% | XXX | XXX | XXX |
| EBITDA Growth | 46% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -288% | XXX | -425% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -337% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 87% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 195% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 499% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
InspireMD acquired XXX companies to date.
Last acquisition by InspireMD was XXXXXXXX, XXXXX XXXXX XXXXXX . InspireMD acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was InspireMD founded? | InspireMD was founded in 2008. |
| Where is InspireMD headquartered? | InspireMD is headquartered in United States of America. |
| How many employees does InspireMD have? | As of today, InspireMD has 86 employees. |
| Who is the CEO of InspireMD? | InspireMD's CEO is Mr. Marvin Slosman. |
| Is InspireMD publicy listed? | Yes, InspireMD is a public company listed on NAS. |
| What is the stock symbol of InspireMD? | InspireMD trades under NSPR ticker. |
| When did InspireMD go public? | InspireMD went public in 1997. |
| Who are competitors of InspireMD? | Similar companies to InspireMD include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of InspireMD? | InspireMD's current market cap is $77.8M |
| What is the current revenue of InspireMD? | InspireMD's last 12 months revenue is $7.1M. |
| What is the current revenue growth of InspireMD? | InspireMD revenue growth (NTM/LTM) is 49%. |
| What is the current EV/Revenue multiple of InspireMD? | Current revenue multiple of InspireMD is 7.6x. |
| Is InspireMD profitable? | Yes, InspireMD is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of InspireMD? | InspireMD's last 12 months EBITDA is -$32.6M. |
| What is InspireMD's EBITDA margin? | InspireMD's last 12 months EBITDA margin is -460%. |
| What is the current EV/EBITDA multiple of InspireMD? | Current EBITDA multiple of InspireMD is -1.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
